New Kids that Don't Grow Up:
The Biotech War for weight loss drugs is heating up:
Altimmune stepped into the ring and got knocked down with a first round knockout. In a Phase 2 trial, patients lost an average of about 9% and 11%, respectively, of their body weight after six months of treatment. But more than half of the people taking Altimmune’s drug experienced nausea, exceeding what was seen in testing of Wegovy.
Pfizer scraps twice-daily weight loss pill danuglipron after study shows ‘high rates’ of adverse side effects. Pfizer says nausea, vomiting among most common side effects reported in clinical trial.
Amgen and Structure Therapeutics also have prospective obesity medicines in clinical testing.
